Clinical Trial

A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Study acronym: MASH
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating the efficacy and safety of UBT251 in MASH subjects. Subjects will be randomly assigned to UBT251 2mg-dose, 4mg-dose，6mg-dose and placebo groups. The entire trial cycle includes a 6-week screening period, a 48-week double-blind treatment period, and a 4-week follow-up period.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-20.
Trial Details
NCT Number NCT07145151
Lead Sponsor The United Bio-Technology (Hengqin) Co., Ltd.
Conditions Metabolic Dysfunction-associated Steatohepatitis (MASH)
Enrollment 156 participants
Start Date 2025-09-30
Primary Completion 2027-06-04 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-20